PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate the clinical efficacy and safety of Shenzhu Guanxin recipe granules (, SGR) in treating patients with intermediate coronary lesions (ICL), and to investigate the potential mechanism though a transcriptome sequencing approach.
METHODS: ICL patients with Qi deficiency and phlegm stasis were adopted and randomly assigned to a case group or a control by random number generator in a 1:1 randomization ratio to evaluate the clinical efficacy.
RESULTS: There was no significant difference between the two groups in coronary computed tomography angiography related indexes in the two groups before and after intervention. Through the gene chip expression analysis, it is finally concluded that there are 355 differential mRNAs (190 up-regulated genes and 165 down regulated genes) when compared the SGR group and placebo group. Through protein-protein interaction network analysis of differentially expressed genes, 10 hub genes were finally obtained: CACNA2D2, CACNA2D3, DNAJC6, FGF12, SGSM2, CACNA1G, LRP6, KIF25, OXTR, UPB1.
CONCLUSIONS: SGR combined with Western Medicine can be safely used to treat ICL patients with Qi deficiency and phlegm stasis. The possible mechanism of action and relevant gene loci and pathway were proposed.
METHODS: ICL patients with Qi deficiency and phlegm stasis were adopted and randomly assigned to a case group or a control by random number generator in a 1:1 randomization ratio to evaluate the clinical efficacy.
RESULTS: There was no significant difference between the two groups in coronary computed tomography angiography related indexes in the two groups before and after intervention. Through the gene chip expression analysis, it is finally concluded that there are 355 differential mRNAs (190 up-regulated genes and 165 down regulated genes) when compared the SGR group and placebo group. Through protein-protein interaction network analysis of differentially expressed genes, 10 hub genes were finally obtained: CACNA2D2, CACNA2D3, DNAJC6, FGF12, SGSM2, CACNA1G, LRP6, KIF25, OXTR, UPB1.
CONCLUSIONS: SGR combined with Western Medicine can be safely used to treat ICL patients with Qi deficiency and phlegm stasis. The possible mechanism of action and relevant gene loci and pathway were proposed.
摘要：
目的:评价参术冠心颗粒的临床疗效和安全性(,SGR）在治疗中度冠状动脉病变（ICL）患者中，并通过转录组测序方法研究潜在的机制。
方法：采用ICL气虚痰瘀证患者，按随机数字发生器1:1随机比例随机分为病例组和对照组，评价临床疗效。
结果：两组干预前后冠状动脉CT造影相关指标比较差异无统计学意义。通过基因芯片表达分析,最后得出结论，与SGR组和安慰剂组相比，有355个差异mRNA（190个上调基因和165个下调基因）。通过差异表达基因的蛋白质-蛋白质相互作用网络分析,最终获得10个hub基因：CACNA2D2、CACNA2D3、DNAJC6、FGF12、SGSM2、CACNA1G、LRP6,KIF25,OXTR,UPB1。
结论：SGR联合西药治疗气虚痰瘀型ICL患者是安全的。提出了可能的作用机制及相关基因位点和通路。
方法：采用ICL气虚痰瘀证患者，按随机数字发生器1:1随机比例随机分为病例组和对照组，评价临床疗效。
结果：两组干预前后冠状动脉CT造影相关指标比较差异无统计学意义。通过基因芯片表达分析,最后得出结论，与SGR组和安慰剂组相比，有355个差异mRNA（190个上调基因和165个下调基因）。通过差异表达基因的蛋白质-蛋白质相互作用网络分析,最终获得10个hub基因：CACNA2D2、CACNA2D3、DNAJC6、FGF12、SGSM2、CACNA1G、LRP6,KIF25,OXTR,UPB1。
结论：SGR联合西药治疗气虚痰瘀型ICL患者是安全的。提出了可能的作用机制及相关基因位点和通路。
